Biomarkers in osteoarthritis

Published on January 24, 2013   31 min

A selection of talks on Clinical Practice

Biomarkers in osteoarthritis. Ali Mobasheri.
The aim of this presentation is to provide an overview of current research on osteoarthritis biomarkers. Highlight the lack of analytical tools and reagents in our currently available toolbox. Discuss the limitations of currently available biomarkers. We will also explore future opportunities and identify key areas that are relevant to the pharmaceutical product pipeline.
This presentation will summarise the definition of osteoarthritis and the biomarkers of osteoarthritis and highlights the need for a better "gold standard" because radiography is currently inadequate. The presentation will also discuss recent developments in biomarker definition and classification and introduce the concepts of "wet" and "dry" biomarkers. I will also discuss post-genomic approaches for the identification of new osteoarthritis biomarkers aimed at early pre-radiographic identification of disease. I will discuss the advent of "combination biomarkers".
Before discussing biomarkers of osteoarthritis, I will need to provide some background information about osteoarthritis.
Osteoarthritis is the most common form of arthritis in humans and companion animals, and it is a major cause of pain, inflammation and loss of mobility.
Osteoarthritis is characterised by progressive deterioration and loss of articular cartilage. It affects load-bearing synovial joints and is associated with ageing and excessive or abnormal joint loading.